We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BIOSYSTEMS

Biosystems researches, develops, produces and markets a wide range of instruments and reagents for clinical chemistry... read more Featured Products: More products

Download Mobile App





BioSystems Highlights New iFOB Integral System at MedLab 2019

By LabMedica International staff writers
Posted on 31 Jan 2019
Print article
Image: The new Fecal Occult blood integral system (Photo courtesy of BioSystems).
Image: The new Fecal Occult blood integral system (Photo courtesy of BioSystems).
BioSystems S.A. (Barcelona, Spain) presented its analytical systems at MedLab Middle East 2019 held in Dubai, UAE, from February 4-7, 2019. MedLab Middle East 2019 attracted more than 19,610 unique visitors and the exhibition floor area housed 678+ exhibitors dedicated to sharing the most recent technology available in the IVD, and medical laboratory market. The MedLab Congress also enjoyed massive growth, welcoming more than 6,000 delegates to the multi-track conferences this year.

At MedLab Middle East 2019, BioSystems presented its new Fecal Occult Blood (iFOB) integral system, which provides a diagnostic solution for FOB testing. Colorectal cancer (CRC) is the third-most common cancer and the fourth-leading cause of cancer-related deaths in the world. CRC is treatable and preventable if it is detected in the early stages, with the detection of fecal occult blood being the key to preventing colorectal cancer.

BioSystems’ new iFOB system is comprised of an easy-to-use stool collection tube for easy sampling at the patient’s home or in the laboratory, an improved immunoturbidimetric assay in the form of a new and high sensitive antibody against human hemoglobin (no cross reaction with non-human Hb), an updated version of the company’s A15 analyzer with a new cap piercing function (no need to decap or recap samples tube after testing), and a dedicated software for fecal samples.

The iFOB system provides an accurate, reliable and safe method for FOB testing, making this test accessible to any kind of laboratory. In addition to FOB tests, BioSystems’ integral system can be updated with new fecal tests such as fecal Calprotectin, Transferrin and Helicobacter pylori, making the system a complete solution for stool samples analysis in the laboratory.

New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.